Erratum: Phase II and III Clinical Studies of Diphtheria-Tetanus-Acellular Pertussis Vaccine Containing Inactivated Polio Vaccine Derived from Sabin Strains (DTaP-sIPV) (The Journal of Infectious Diseases (2013) 208:2 (275–283) DOI: 10.1093/infdis/jit155);Phase II and III clinical studies of diphtheria-tetanus-acellular pertussis vaccine containing inactivated polio vaccine derived from sabin strains (DTaP-sIPV)

Journal of Infectious Diseases

Volumn 208, Issue 2, 2013, Pages 275-283

  Okada, Kenji ^a   Miyazaki, Chiaki ^b   Kino, Yoichiro ^c   Ozaki, Takao ^d   Hirose, Mizuo ^e   Ueda, Kohji ^f  

^a FUKUOKA NATIONAL HOSPITAL   (Japan)

^b Fukuoka West Rehabilitation Center for Children   (Japan)

^c Chemo Sero Therapeutic Research Institute   (Japan)

^d Aichi Prefectural Welfare Federation of Agriculture Co operative Associations Konan Kosei Hospital   (Japan)

^e Hirose Children's Clinic   (Japan)

^f Seinan Jo Gakuin University   (Japan)

Author keywords

clinical study; combination vaccine; DTaP; IPV; Sabin strain

Indexed keywords

DIPHTHERIA PERTUSSIS POLIOMYELITIS TETANUS VACCINE; ORAL POLIOMYELITIS VACCINE; PLACEBO;

ANTIBODY TITER; ARTICLE; BORDETELLA PERTUSSIS; CHILD; CONTROLLED STUDY; COUGHING; DECREASED APPETITE; DIARRHEA; DIPHTHERIA; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG ERUPTION; DRUG FEVER; DRUG FORMULATION; DRUG MEGADOSE; FEMALE; HUMAN; HUMAN EXPERIMENT; IMMUNIZATION; IMMUNOGENICITY; INFANT; INJECTION SITE ERYTHEMA; INJECTION SITE INDURATION; INJECTION SITE REACTION; INJECTION SITE SWELLING; MALE; MULTICENTER STUDY; NORMAL HUMAN; PHARYNGEAL ERYTHEMA; PHARYNX DISEASE; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; POLIOMYELITIS VIRUS; PRESCHOOL CHILD; PRIORITY JOURNAL; PRODUCTIVE COUGHING; RANDOMIZED CONTROLLED TRIAL; RHINORRHEA; SCHOOL CHILD; TETANUS; VIRUS NEUTRALIZATION; VIRUS STRAIN; VOMITING;

EID: 84879326905     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiab028     Document Type: Erratum

References (29)

1. WHO. Wild Poliovirus 2007-2012. http://www.polioeradication.org/Portals/ 0/Document/Data&Monitoring/Wild-poliovirus-list-2007-2012- 06June.pdf. Accessed 7 December 2012
2. Hao L, Toyokawa S, Kobayashi Y. Poisson-model analysis of the risk of vaccine-associated paralytic poliomyelitis in Japan between 1971 and 2000. Jpn J Infect Dis 2008; 61:100-3 (Pubitemid 351663800)
3. Sutter RW, Kew OM, Cochi SL. Poliovirus vaccine-live. In: Plotkin SA, Orenstein WA, Offit P, eds. Vaccines 5th ed. Saunders Elsevier, 2008: 631-85
4. WHO global action plan to minimize poliovirus facility-associated risk after eradication of wild polioviruses and cessation of routine OPV use. http://www.polioeradication.org/Portals/0/Document/Resources/PostEradication/ GAP3-2009.pdf. Accessed 7 December 2012
5. Kreeftenberg H, van der Velden T, Kersten G, van der Heuvel N, de Bruijn M. Technology transfer of Sabin-IPV to new developing country markets. Biologicals 2006; 34:155-8 (Pubitemid 43765774)
6. Bakker WA, Thomassen YE, van't Oever AG, et al. Inactivated polio vaccine development for technology transfer using attenuated Sabin poliovirus strains to shift from Salk-IPV to Sabin-IPV. Vaccine 2011; 29:7188-96
7. Murph JR, Grose C, McAndrew P, et al. Sabin inactivated trivalent poliovirus vaccine: first clinical trial and seroimmunity survey. Pediatr Infect Dis J 1988; 7:760-5 (Pubitemid 18266221)
8. Doi Y, Abe S, Yamamoto H, et al. Progress with inactivated poliovirus vaccines derived from the Sabin strains. Dev Biol (Basel) 2001; 105: 163-9
9. Liao G, Li R, Li C, et al. Safety and immunogenicity of inactivated poliovirus vaccine made from Sabin strains: a phase II, randomized, positive-controlled trial. J Infect Dis 2012; 205:237-43
10. Simizu B, Abe S, Yamamoto H, et al. Development of inactivated poliovirus vaccine derived from Sabin strains. Biologicals 2006; 34:151-4
11. Kersten G, Hazendonk T, Beuvery C. Antigenic and immunogenic properties of inactivated polio vaccine made from Sabin strains. Vaccine 1999; 17:2059-66 (Pubitemid 29172378)
12. Ginnaga A, Morokuma K, Aihara K, et al. Characterization and clinical study on the acellular pertussis vaccine produced by a combination of column purified pertussis toxin and filamentous hemagglutinin. Tokai J Exp Clin Med 1988; 13(Suppl):59-69 (Pubitemid 20128221)
13. Kimura M, Kuno-Sakai H, Kamiya H, et al. Immunogenicity and reactogenicity of the component acellular pertussis vaccine produced by a combination of column purified pertussis toxin and filamentous haemagglutinin. Acta Paediatr Jpn 1995; 37:562-74
14. Huang LM, Lee CY, Lin TY, Chen JM, Lee PI, Hsu CY. Responses to primary and a booster dose of acellular, component, and whole-cell pertussis vaccines initiated at 2 months of age. Vaccine 1996; 14: 916-22
15. Kuno-Sakai H, Kimura M. Safety and efficacy of acellular pertussis vaccine in Japan, evaluated by 23 years of its use for routine immunization. Pediatr Int 2004; 46:650-5 (Pubitemid 40100549)
16. Okada K, Ohashi Y, Matsuo F, Uno S, Soh M, Nishima S. Effectiveness of an acellular pertussis vaccine in Japanese children during a non-epidemic period: a matched case-control study. Epidemiol Infect 2009; 137:124-30
17. Manual for the virological investigation of poliomyelitis. WHO/EPI/CDS/POLIO/90.1. http://whqlibdoc.who.int/hq/1990/WHO-EPI-CDS- POLIO-90.1.pdf. Accessed 7 December 2012
18. Plotkin SA, Vidor E. Poliovirus vaccine-inactivated. In: Plotkin SA, Orenstein WA, Offit P, eds. Vaccines. 5th ed. Saunders Elsevier, 2008:605-29
19. Kato T. DPT. J Pediatr Practice 1990; 53:2275-81
20. Vitek CR, Wharton M. Diphtheria toxoid. In: Plotkin SA, Orenstein WAOffit P, eds. Vaccines 5th ed. Saunders Elsevier, 2008; 139-56
21. Wassilak SGF, Roper MH, Kretsinger K, Orenstein WA. Tetanus toxoid. In: Plotkin SA, OrensteinWA, Offit P, eds. Vaccines 5th ed. Saunders Elsevier, 2008;805-39
22. Francis TJ, Korns RF. Evaluation of 1954 field trial of poliomyelitis vaccine: synopsis of summary report. Am J Med Sci 1955; 229:603-12
23. Melnick JL, Benyesh-Melnick M, Pena R, Yow M. Effectiveness of Salk vaccine. Analysis of virologically confirmed cases of paralytic and nonparalytic poliomyelitis. J Am Med Assoc 1961; 175:1159-62
24. Robertson SE, Traverso HP, Drucker JA, et al. Clinical efficacy of a new, enhanced-potency, inactivated poliovirus vaccine. Lancet 1988; 331: 897-9 (Pubitemid 18096742)
25. Hammon WM, Coriell LL, Wehrle PF, Stokes J Jr. Evaluation of Red Cross gamma globulin as a prophylactic agent for poliomyelitis 4. Final report of results based on clinical diagnoses. J Am Med Assoc 1953; 151:1272-85
26. Dragunsky EM, Ivanov AP, Wells VR, et al. Evaluation of immunogenicity and protective properties of inactivated poliovirus vaccines: a new surrogate method for predicting vaccine efficacy. J Infect Dis 2004; 190:1404-12 (Pubitemid 39332179)
27. WHO. Confirmed international spread of wild poliovirus from Pakistan. http://www.who.int/csr/don/2011-09-20/en/index.html. Accessed 7 December 2012
28. National Institute for Biological Standards and Control. WHO International Standard Anti-Measles Serum, Human and Anti-Poliovirus serum Types 1,2 and 3. (66/202). http://www.nibsc.ac.uk/documents/ifu/66-202.pdf. Accessed 7 December 2012.
29. McBean AM, Thoms ML, Albrecht P, Cuthie JC, Bernier R. Serologic response to oral polio vaccine and enhanced-potency inactivated polio vaccine. Am J Epidemiol. 1988; 128:615-28